Saturday, June 20, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,771
Drugs linked 4,798

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 863 of 1,261

  1. US 8481551

    Gyrase and topoisomerase IV inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Jul 9, 2013 · Expires Jul 4, 2033

    granted

  2. US 8481569

    Iminopyridine derivatives and use thereof

    Takeda Pharmaceutical Company Limited · Granted Jul 9, 2013 · Expires Jul 4, 2033

    granted

  3. US 8481757

    Compounds and compositions useful in the treatment of malaria

    The Regents of the University of California · Granted Jul 9, 2013 · Expires Jul 4, 2033

    granted

  4. US 8481760

    Inhibition and treatment of prostate cancer metastasis

    Northwestern University · Granted Jul 9, 2013 · Expires Jul 4, 2033

    granted

  5. US 8481578

    Thiophene-carboxamides useful as inhibitors of protein kinases

    Vertex Pharmaceuticals Incorporated · Granted Jul 9, 2013 · Expires Jul 4, 2033

    granted

  6. US 8481738

    Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

    Neurocrine Biosciences, Inc. · Granted Jul 9, 2013 · Expires Jul 4, 2033

    granted

  7. US 8481599

    Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism

    TONIX PHARMACEUTICALS HOLDING CORP · Granted Jul 9, 2013 · Expires Jul 4, 2033

    granted

  8. US 8481693

    Virus like particle purification

    Takeda Vaccines (Montana), Inc. · Granted Jul 9, 2013 · Expires Jul 4, 2033

    granted

  9. US 8480637

    Nanochanneled device and related methods

    The Board of Regents of the University of Texas System · Granted Jul 9, 2013 · Expires Jul 4, 2033

    granted

  10. US 8481048

    Methods for preparing immunogenic conjugates

    The United States of America as Represented by The Secretary of the Department of Health and Human Services National Institutes of Health Office of Technology Transfer · Granted Jul 9, 2013 · Expires Jul 4, 2033

    granted

  11. US 8481038

    Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins

    Five Prime Therapeutics, Inc. · Granted Jul 9, 2013 · Expires Jul 4, 2033

    granted

  12. US 8481010

    Covalently bonding nail primer

    Creative Nail Design Inc. · Granted Jul 9, 2013 · Expires Jul 4, 2033

    granted

  13. US 8481006

    Melt formula

    New Sunshine, LLC · Granted Jul 9, 2013 · Expires Jul 4, 2033

    granted

  14. US 8481524

    c-MET protein kinase inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Jul 9, 2013 · Expires Jul 4, 2033

    granted

  15. US 8481313

    Retinal pigment epithelial stem cells

    REGENERATIVE RESEARCH FOUNDATION · Granted Jul 9, 2013 · Expires Jul 4, 2033

    granted

  16. US 8481289

    Triple acting antimicrobials that are refractory to resistance development

    The United States of America, as represented by the Secretary of Agriculture · Granted Jul 9, 2013 · Expires Jul 4, 2033

    granted

  17. US 8481095

    Method for anti-oxidation, inhibiting activity and/or expression of matrix metalloproteinase, and/or inhibiting phosporylation of mitogen-activated protein kinase using flemingia macrophylla extract

    China Medical University · Granted Jul 9, 2013 · Expires Jul 4, 2033

    granted

  18. US 8481046

    VEGF antagonist formulations for intravitreal administration

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 9, 2013 · Expires Jul 4, 2033

    granted

  19. US 8481563

    8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists

    Theravance, Inc. · Granted Jul 9, 2013 · Expires Jul 4, 2033

    granted

  20. US 8481549

    Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents

    Theravance, Inc. · Granted Jul 9, 2013 · Expires Jul 4, 2033

    granted

  21. US 8481538

    Heterocyclic inhibitors of c-Met and uses thereof

    Vertex Pharmaceuticals Incorporated · Granted Jul 9, 2013 · Expires Jul 4, 2033

    granted

  22. US 8481529

    Combination cancer chemotherapy

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Jul 9, 2013 · Expires Jul 4, 2033

    granted

  23. US 8481552

    Solid forms of gyrase inhibitor (R)-1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-YL]-7-(tetrahydrofuran-2-yl)-1H-benzimidazol-2-YL]urea

    Vertex Pharmaceuticals Incorporated · Granted Jul 9, 2013 · Expires Jul 4, 2033

    granted

  24. US 8481507

    Micro-RNAs that control myosin expression and myofiber identity

    The Board of Regents of the University of Texas System · Granted Jul 9, 2013 · Expires Jul 4, 2033

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.